Importance:
Increasing numbers of women experience pregnancy around the time of, or after, a diagnosis of breast cancer. Understanding the effect of pregnancy on survival in women with breast cancer will help in the counseling and treatment of these women.
Objective:
To compare the overall survival of women diagnosed with breast cancer during pregnancy or in the postpartum period with that of women who had breast cancer but did not become pregnant.
Design, Setting, And Participants:
This population-based, retrospective cohort study linked health administrative databases in Ontario, Canada, comprising 7553 women aged 20 to 45 years at the time of diagnosis with invasive breast cancer, from January 1, 2003, to December 31, 2014.
Exposures:
Any pregnancy in the period from 5 years before, until 5 years after, the index date of the diagnosis of breast cancer. Women were classified into the following 4 exposure groups: no pregnancy (the referent), pregnancy before breast cancer, pregnancy-associated breast cancer, and pregnancy following breast cancer.
Main Outcomes And Measures:
Five-year actuarial survival rates for all exposure groups, age-adjusted and multivariable hazard ratios [HRs] of pregnancy for overall survival for all exposure groups, and time-dependent hazard ratios for women with pregnancy following breast cancer.
Results:
Among the 7553 women in the study (mean age at diagnosis, 39.1 years; median, 40 years; range, 20-44 years) the 5-year actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy, 85.3% (95% CI, 82.8%-87.8%) for women with pregnancy before breast cancer (age-adjusted hazard ratio, 1.03; 95% CI, 0.85-1.27; P = .73), and 82.1% (95% CI, 78.3%-85.9%) for women with pregnancy-associated breast cancer (age-adjusted hazard ratio, 1.18; 95% CI, 0.91-1.53; P = .20). The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%) for women who had pregnancy 6 months or more after diagnosis of breast cancer, vs 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy) (age-adjusted HR, 0.22; 95% CI, 0.10-0.49; P < .001).
Conclusions And Relevance:
Pregnancy did not adversely affect survival in women with breast cancer. For breast cancer survivors who wish to conceive, the risk of death is lowest if pregnancy occurs 6 months or more after diagnosis.
Citing Articles
Outcome of Patients with Pregnancy-Associated Breast Cancer Who Have Subsequent Pregnancies.
Doll A, Lipsyc-Sharf M, Sim M, Baker J, Kapoor N
Ann Surg Oncol. 2024; 31(11):7538-7546.
PMID: 38987368
PMC: 11452428.
DOI: 10.1245/s10434-024-15798-5.
Breast Cancer in Pregnant Young Women: Clinicopathological Profile, Survival, and Pregnancy Outcomes.
Ramirez-Torres N, Rivas-Ruiz R, Reyes-Lopez A
Cureus. 2023; 15(10):e47578.
PMID: 38022007
PMC: 10666668.
DOI: 10.7759/cureus.47578.
The Association Between Pregnancy Timing and Cumulative Exposure on Survival in Melanoma.
Bateni S, Sutradhar R, Everett K, Wright F, Look Hong N
Ann Surg Oncol. 2023; 30(11):6332-6338.
PMID: 37386307
DOI: 10.1245/s10434-023-13819-3.
Pregnancy in a Young Patient with Metastatic HER2-Positive Breast Cancer-Between Fear of Recurrence and Desire to Procreate.
Oprean C, Ciocoiu A, Segarceanu N, Moldoveanu D, Stan A, Hoinoiu T
Curr Oncol. 2023; 30(5):4833-4843.
PMID: 37232822
PMC: 10217573.
DOI: 10.3390/curroncol30050364.
Pregnancy-associated breast cancer: does timing of presentation affect outcome?.
Crown A, McCartan D, Curry M, Patil S, Kamer S, Goldfarb S
Breast Cancer Res Treat. 2023; 198(2):283-294.
PMID: 36662395
DOI: 10.1007/s10549-022-06833-8.
Pregnancy After Breast Cancer - Prognostic Safety and Pregnancy Outcomes According to Oestrogen Receptor Status: A Systematic Review.
Nolan K, Boland M, Hill A
J Breast Cancer. 2022; 25(6):443-453.
PMID: 36479601
PMC: 9807324.
DOI: 10.4048/jbc.2022.25.e45.
Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende E, Dahhan T, Beerendonk C, Fleischer K, Stoop D, Bos A
Hum Reprod. 2022; 37(8):1786-1794.
PMID: 35776109
PMC: 9340107.
DOI: 10.1093/humrep/deac145.
Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study.
Rauh-Hain J, Zubizarreta J, Nitecki R, Melamed A, Fu S, Jorgensen K
Cancer. 2022; 128(17):3243-3253.
PMID: 35767282
PMC: 9378486.
DOI: 10.1002/cncr.34371.
Which Has a Greater Impact on the Recurrence in Young Breast Cancer Patients: Recent Childbirth or Recent Breastfeeding?.
Yan C, Bai J, Bao S, Xia Y, Yu H, Yin Y
Breast J. 2022; 2022:5823867.
PMID: 35711888
PMC: 9187285.
DOI: 10.1155/2022/5823867.
Alpha-fetoprotein-producing recurrent nasopharyngeal carcinoma: A case report.
Yang Z, Luo M, Liu L, Cai M, Liang Y, Chen Q
SAGE Open Med Case Rep. 2021; 9:2050313X211057704.
PMID: 34777811
PMC: 8573489.
DOI: 10.1177/2050313X211057704.
Timing of Presentation and Outcomes of Women with Stage IV Pregnancy-Associated Breast Cancer (PABC).
Matar R, Crown A, Sevilimedu V, Goldfarb S, Gemignani M
Ann Surg Oncol. 2021; 29(3):1695-1702.
PMID: 34709494
PMC: 9470501.
DOI: 10.1245/s10434-021-10901-6.
Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.
Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C
Breast Cancer. 2021; 29(1):1-8.
PMID: 34665435
DOI: 10.1007/s12282-021-01307-z.
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.
Jerzak K, Lipton N, Nofech-Mozes S, Boles D, Slodkowska E, Pond G
Breast Cancer Res Treat. 2021; 189(3):797-806.
PMID: 34318391
DOI: 10.1007/s10549-021-06327-z.
Conception after chemotherapy: post-chemotherapy method of conception and pregnancy outcomes in breast cancer patients.
Abel M, Wald K, Sinha N, Letourneau J, Simbulan R, Mok-Lin E
J Assist Reprod Genet. 2021; 38(7):1755-1765.
PMID: 33740176
PMC: 8324739.
DOI: 10.1007/s10815-021-02133-0.
Impact of pregnancy on cancer survival: Experience at a tertiary care hospital.
Dur-E-Shahwar , Irfan S, Shamsul Islam Z, Sheikh L
Pak J Med Sci. 2021; 37(2):335-338.
PMID: 33679909
PMC: 7931303.
DOI: 10.12669/pjms.37.2.3525.
The Effect of Subsequent Pregnancy on Prognosis in Young Breast Cancer Patients (≤35 Years Old) According to Hormone Receptor Status.
Li Y, Zhang Y, Wang S, Lu S, Song Y, Liu H
Cancer Manag Res. 2021; 13:1505-1515.
PMID: 33623430
PMC: 7894832.
DOI: 10.2147/CMAR.S290566.
Gonadotrophin stimulation and risk of relapse in breast cancer.
Fredriksson A, Rosenberg E, Einbeigi Z, Bergh C, Strandell A
Hum Reprod Open. 2021; 2021(1):hoaa061.
PMID: 33501382
PMC: 7810817.
DOI: 10.1093/hropen/hoaa061.
[Safe pregnancy after breast cancer treatment in patients carrying BRCA mutations?].
Souchon R
Strahlenther Onkol. 2020; 197(2):159-161.
PMID: 33313957
DOI: 10.1007/s00066-020-01726-5.
Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé à La Grossesse) network.
Boudy A, Ferrier C, Selleret L, Zilberman S, Arfi A, Sussfeld J
Breast. 2020; 54:311-318.
PMID: 33271423
PMC: 7711283.
DOI: 10.1016/j.breast.2020.11.013.
Gender-specific aspects related to type of fertility preservation strategies and access to fertility care.
Perachino M, Massarotti C, Razeti M, Parisi F, Arecco L, Damassi A
ESMO Open. 2020; 5(Suppl 4):e000771.
PMID: 33115753
PMC: 7594356.
DOI: 10.1136/esmoopen-2020-000771.